Streetbeat News

Analyst Ratings

TTWO

Wells Fargo analyst Brian Fitzgerald has maintained an Overweight rating on Take-Two Interactive (NASDAQ:TTWO) and raised the price target from $160 to $170.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:57 pm

JRVR

James River Group Holdings' shares are trading lower due to worse-than-expected Q3 revenue results and multiple firms downgrading the stock and lowering their price targets.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:56 pm

PLTK

Wells Fargo analyst Brian Fitzgerald has maintained an Equal-Weight rating on Playtika Holding (NASDAQ:PLTK) and lowered the price target from $11 to $9.5.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:55 pm

FOUR

Wells Fargo analyst Andrew Bauch maintains an Overweight rating on Shift4 Payments (NYSE:FOUR) and raises the price target from $55 to $60.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:53 pm

STKS

Wedbush analyst Nick Setyan has maintained a Neutral rating on The One Group Hospitality (NASDAQ:STKS) and lowered the price target from $7.5 to $5.25.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:53 pm

AVDX

Wells Fargo analyst Andrew Bauch maintains an Equal-Weight rating on AvidXchange Holdings (NASDAQ:AVDX) and raises the price target from $9 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:52 pm

AFRM

Wells Fargo analyst Andrew Bauch maintains an Equal-Weight rating on Affirm Holdings (NASDAQ:AFRM) and raises the price target from $17 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:51 pm

FATE

Wedbush analyst David Nierengarten has maintained a Neutral rating on Fate Therapeutics (NASDAQ:FATE) and lowered the price target from $6 to $3.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:50 pm

ELME

Wells Fargo analyst Blaine Heck has maintained an Equal-Weight rating on Elme Communities (NYSE:ELME) and lowered the price target from $15.5 to $14.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:48 pm

BIIB

Biogen shares are trading lower following the company's Q3 financial results and weak FY23 guidance. Wedbush has maintained a Neutral rating on the stock and lowered its price target from $266 to $239.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:47 pm